Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis

OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Roodselaar, Jay, Zhou, Yifan, Leppert, David, Hauser, Anja E., Urich, Eduard, Anthony, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931641/
https://www.ncbi.nlm.nih.gov/pubmed/33653962
http://dx.doi.org/10.1212/NXI.0000000000000975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931641/
https://www.ncbi.nlm.nih.gov/pubmed/33653962
http://dx.doi.org/10.1212/NXI.0000000000000975

Ejemplares similares